Lopinavir-ritonavir Shows No Significant Benefit In COVID-19

Researchers from the UK and China conducted a clinical trial to find the efficacy of lopinavir and ritonavir against COVID-19. This was a randomized controlled trial involving 199 COVID-19 confirmed and hospitalized patients. Of these, 100 received standard care, and 99 received the drug combination. The results revealed that

• In both treatment approaches, the time to clinical improvement was similar.

• The percentage of clinical improvement at day 14 for those on lopinavir and ritonavir was 45.5% as compared to 30% on standard care.

• The need for steroids was 33% for patients receiving standard care and 35.7% for those receiving standard care.

• Clinical time to the improvement of symptoms was one day shorter for lopinavir-ritonavir than standard care alone on an average.

• Patients receiving lopinavir-ritonavir had a shorter stay in the ICU compared to standard care.

• Serious side-effects were common in those receiving standard care. GI side effects were common in the lopinavir-ritonavir group.

• Viral loads at various time points were similar for both groups.

The study concluded that lopinavir-ritonavir did not provide significant benefit in patients hospitalized due to COVID-19.

To know more about origin, virology of COVID-19, Click here

To know more about emerging themes in COVID-19, Click here

To know more about how WhiteCoats can help you in your professional advancement, visit www.whitecoats.com

Want to set up an online consultation for your practice, Click here

Ref link: https://www.nejm.org/doi/full/10.1056/NEJMoa2001282